Tina Bhutani1, John Koo. 1. University of California, San Francisco, Psoriasis and Skin Treatment Center, San Francisco, California 94118, USA. tinabhutanimd@gmail.com
Abstract
BACKGROUND: Etanercept and adalimumab are the most widely used biologic agents for psoriasis today. Large phase III trials have elucidated the much higher efficacy of adalimumab over etanercept; however, no head-to-head comparison data exist for these two medications. OBJECTIVE: We report four cases of patients well controlled with Enbrel who flared when switched to adalimumab. In all four cases, the patient's psoriasis improved when switched back to etanercept. CONCLUSION: This brief report is intended to alert clinicians of the possibility that, despite the well-known average efficacy advantage of adalimumab over etanercept, some psoriasis patients experience better clinical outcome with etanercept than adalimumab. Therefore, despite the general efficacy difference between these two TNF inhibitors, it may be worth keeping in mind etanercept as an option in patients who have failed with adalimumab.
BACKGROUND: Etanercept and adalimumab are the most widely used biologic agents for psoriasis today. Large phase III trials have elucidated the much higher efficacy of adalimumab over etanercept; however, no head-to-head comparison data exist for these two medications. OBJECTIVE: We report four cases of patients well controlled with Enbrel who flared when switched to adalimumab. In all four cases, the patient's psoriasis improved when switched back to etanercept. CONCLUSION: This brief report is intended to alert clinicians of the possibility that, despite the well-known average efficacy advantage of adalimumab over etanercept, some psoriasispatients experience better clinical outcome with etanercept than adalimumab. Therefore, despite the general efficacy difference between these two TNF inhibitors, it may be worth keeping in mind etanercept as an option in patients who have failed with adalimumab.